Refractory Thrombus in Patients With Acute Coronary Syndrome Clinical Trial
— SolitaireOfficial title:
Feasibility Trial Evaluating Efficacy and Safety of Solitaire™ Thrombus Retrieval Device in the Management of Refractory Thrombus in Patients With Acute Coronary Syndrome
The study is designed as a multicentre open label prospective feasibility trial to capture preliminary efficacy and safety information on Solitaire device to plan an appropriate pivotal study.
| Status | Recruiting |
| Enrollment | 51 |
| Est. completion date | September 30, 2022 |
| Est. primary completion date | June 30, 2022 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 22 Years to 80 Years |
| Eligibility | Inclusion Criteria: Subjects meeting all of the inclusion criteria listed below will be included in this study: 1. Index event of ST segment elevation or non-ST segment elevation MI or Unstable Angina defined as: 1. Presentation to hospital with symptoms of myocardial ischemia (Chest pain or angina equivalent) lasting for =10 minutes at rest AND 1 of the following: 2. Persistent ST segment elevation =1mm (0.1 mV) in two or more contiguous limb leads or =2mm (0.2 mV) in ) in one or more contiguous precordial leads OR 3. New or presumed new left bundle branch block (LBBB) OR 4. ST segment depression =1mm (0.1 mV) in two or more contiguous leads (not known to be pre-existing or due to a known cause such as LV hypertrophy or digoxin) OR 5. Troponin T or I greater than the laboratory upper normal limit. 2. Referred for urgent or emergency PCI AND Thrombus burden of TG 4 or above OR TIMI flow grade of 1 or less in at least one native infarct related artery following either 1. Manual aspiration thrombectomy OR 2. Balloon Angioplasty OR 3. AngioJet RT OR 4. Patient having deferred PCI due to heavy thrombus but continue to demonstrate recalcitrant thrombus upon repeat angiography. Exclusion Criteria: Subjects meeting any of the exclusion criteria listed below will be excluded from this study: 1. Age = 21 years 2. Cardiogenic shock 3. killip class 3 or above at presentation 4. Known relative contraindications for the use of Solitaire: 1. Prior stent in infarct related artery 2. Significant proximal stenosis OR Ostial lesion at angiography 3. Extensive calcification 5. Life expectancy less than six months due to non-cardiac condition 6. Participants categorised as vulnerable subjects (ex: prisoners, pregnant women, and mentally disabled persons) 7. Patients at high risk of being lost to follow up (ex: non-residents) 8. Participation in any study with an investigational drug or device within the last 30 days 9. Patients who are unable to provide informed consent prior to any procedure . |
| Country | Name | City | State |
|---|---|---|---|
| Singapore | Changi General Hospital (CGH) Changi General Hospital | Singapore | |
| Singapore | Khoo Teck Puat Hospital | Singapore | |
| Singapore | National Heart Centre Singapore (NHCS) | Singapore | Singaproe |
| Singapore | National University Heart Centre Singapore (NUHCS) | Singapore | |
| Singapore | Tan Tock Seng Hospital (TTSH) | Singapore |
| Lead Sponsor | Collaborator |
|---|---|
| Paul Ong |
Singapore,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Rate of successful recanalization defined as an immediate post-procedure Thrombolysis in Myocardial Infarction (TIMI) flow of 2 or 3. | Primary Efficacy Endpoint | immediate post-procedure | |
| Primary | Occurrence of any stroke | Occurrence of any stroke, defined as the presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours, from immediate post-procedure up to 30 days. | immediate post-procedure up to 30 days | |
| Primary | Incidence of study device-related Serious Adverse Events (SAEs) up to 30 days. | Primary Safety Endpoint | up to 30 days | |
| Primary | Incidence of emboli in new territory (ENT) at 24 hrs ± 8 hrs post procedure (ENT: Embolization territories outside of the target downstream territory). | Primary Safety Endpoint | at 24 hours ± 8 hours post procedure | |
| Secondary | Rate of successful thrombus resolution defined as an immediate post-procedure thrombus burden of thrombus grade (TG) 1 or less | Secondary Endpoints | immediate post-procedure | |
| Secondary | Rate of successful recanalization defined as a reduction in corrected TIMI frame count after use of the Solitaire device. | Secondary Endpoints | immediate post-procedure | |
| Secondary | Rate of successful myocardial perfusion defined as an immediate post-procedure myocardial blush grade (MBG) of 2 or more | Secondary Endpoints | immediate post-procedure | |
| Secondary | Rate of device success defined as successful delivery and retrieval of the device without complication | Secondary Endpoints | immediate post- procedure | |
| Secondary | Occurrence of major adverse cardiac and cerebrovascular events (MACCE) | Occurrence of major adverse cardiac and cerebrovascular events (MACCE), defined as composite of all cause death, myocardial infarction, target vessel revascularisation or stroke, up to one year post-procedure. | up to one year post-procedure | |
| Secondary | All-cause mortality through 90 days post procedure. | Secondary Endpoints | 90 days post procedure |